SOX9 and cancer: The upregulation of SOX9 expression reduces the expression of E-cadherin and increases the expression of vimentin and α-SMA, thereby promoting the invasion and metastasis of cancer cells (37–39) and decreasing the survival of patients with CCA by conferring chemoresistance (39).